Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Bruns

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|October 16, 2012
Rules for identifying potentially reactive or promiscuous compoundsRobert F Bruns, Ian A Watson
Advances in Pharmacology (San Diego, Calif.)|August 6, 2019
Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A Svensson, Junliang Hao, Robert F Bruns
Molecular Pharmacology|February 21, 2023
Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 ReceptorXushan Wang, Erik J Hembre, Paul J Goldsmith, et al.
Psychopharmacology|March 24, 2023
Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primateStacy A Castner, Linli Zhang, Charles R Yang, et al.
Molecular Pharmacology|August 17, 2018
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 ReceptorXushan Wang, Beverly A Heinz, Yue-Wei Qian, et al.
Bioorganic & Medicinal Chemistry|January 20, 2007
Azetidinones as vasopressin V1a antagonistsChristophe D Guillon, Gary A Koppel, Michael J Brownstein, et al.
Neuropharmacology|November 6, 2017
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disordersRobert F Bruns, Stephen N Mitchell, Keith A Wafford, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 5, 2016
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or TachyphylaxisKjell A Svensson, Beverly A Heinz, John M Schaus, et al.
Journal of Medicinal Chemistry|September 19, 2019
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 ReceptorJunliang Hao, James P Beck, John M Schaus, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|October 16, 2012
Rules for identifying potentially reactive or promiscuous compoundsRobert F Bruns, Ian A Watson
Advances in Pharmacology (San Diego, Calif.)|August 6, 2019
Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A Svensson, Junliang Hao, Robert F Bruns
Molecular Pharmacology|February 21, 2023
Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 ReceptorXushan Wang, Erik J Hembre, Paul J Goldsmith, et al.
Psychopharmacology|March 24, 2023
Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primateStacy A Castner, Linli Zhang, Charles R Yang, et al.
Molecular Pharmacology|August 17, 2018
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 ReceptorXushan Wang, Beverly A Heinz, Yue-Wei Qian, et al.
Bioorganic & Medicinal Chemistry|January 20, 2007
Azetidinones as vasopressin V1a antagonistsChristophe D Guillon, Gary A Koppel, Michael J Brownstein, et al.
Neuropharmacology|November 6, 2017
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disordersRobert F Bruns, Stephen N Mitchell, Keith A Wafford, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 5, 2016
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or TachyphylaxisKjell A Svensson, Beverly A Heinz, John M Schaus, et al.
Journal of Medicinal Chemistry|September 19, 2019
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 ReceptorJunliang Hao, James P Beck, John M Schaus, et al.
Pageof 1